Valuation: DiaMedica Therapeutics Inc.

Market Cap 582M 410M 358M 329M 307M 39.04B 591M 3.96B 1.54B 19.19B 1.54B 1.51B 66.14B P/E 2026 *
-9.18x
P/E 2027 * -8.66x
Enterprise Value 582M 410M 358M 329M 307M 39.04B 591M 3.96B 1.54B 19.19B 1.54B 1.51B 66.14B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
56.7%
Yield 2026 *
-
Yield 2027 * -
1 day+2.42%
1 week+16.34%
Current month+8.24%
1 month+35.11%
3 months+17.59%
6 months-10.77%
Current year-4.27%
1 week 6.98
Extreme 6.98
7.74
1 month 5.24
Extreme 5.245
7.74
Current year 5.24
Extreme 5.245
9.04
1 year 3.57
Extreme 3.57
10.42
3 years 1.94
Extreme 1.9382
10.42
5 years 1.12
Extreme 1.12
10.42
10 years 1.12
Extreme 1.12
13.77
Manager TitleAgeSince
Chief Executive Officer 54 2009-12-31
Director of Finance/CFO 60 2018-03-31
Chief Tech/Sci/R&D Officer 60 2025-08-10
Director TitleAgeSince
Director/Board Member 70 2010-08-09
Chairman 54 2008-03-31
Chairman 60 2024-12-31
Date Insider Type Main position Quantity % Market Cap.
05-31Option

Chief Executive Officer

380,000 0.7052%
05-31Option

Director

40,412 0.0750%
05-31Option

Chairman

51,189 0.0950%
Change 5-day change 1-year change 3-year change Capi.($)
+2.42%+16.34%+102.66%+93.40% 411M
+0.68%+5.92%+77.86%+136.97% 59.1B
+2.32%+5.03%+75.26%+92.31% 55.19B
+3.86%+6.93%-11.32%-10.57% 24.67B
+4.30%+7.95%+14.11%+440.44% 24.19B
-1.17%+5.22%+48.18%-2.83% 19.69B
-0.29%+9.78%+43.90%-29.12% 17.56B
0.00%+20.78%+186.15%+347.42% 16.22B
+0.20%+14.78%+41.88% - 14.84B
+3.50%+1.97%+21.02%+193.33% 14.04B
Average +1.58%+10.10%+59.97%+140.15% 24.59B
Weighted average by Cap. +1.60%+6.50%+59.03%+135.91%

Financials

2026 *2027 *
Net sales - -
Net income -63.21M -44.5M -38.9M -35.75M -33.33M -4.24B -64.17M -429M -167M -2.08B -167M -163M -7.18B -78.02M -54.93M -48.02M -44.13M -41.14M -5.23B -79.21M -530M -206M -2.57B -206M -202M -8.86B
Net Debt - -
Logo DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
Employees
35
Date Price Change Volume
26-07-02 US$7.620 +2.42% 216,485
26-07-01 US$7.440 +5.68% 348,165
26-06-30 US$7.040 -2.49% 301,655
26-06-29 US$7.220 +10.23% 395,092
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.620USD
Average target price
15.50USD
Spread / Average Target
+103.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMAC Stock